Navigation Links
Arete Therapeutics Names James Sabry, M.D., Ph.D., President and Chief Executive Officer
Date:7/8/2008

HAYWARD, Calif., July 8 /PRNewswire/ -- Arete Therapeutics Inc., a privately-held biopharmaceutical company developing first-in-class soluble epoxide hydrolase (s-EH) inhibitors, today announced the appointment of James Sabry, M.D., Ph.D., as president and chief executive officer. Dr. Sabry has been a strategic advisor and member of the board of directors since March 2008. Dr. Sabry succeeds Dinesh Patel in the position of president and chief executive officer, who will remain as a consultant to the company.

"James brings a wealth of drug discovery, development, and biotechnology management expertise to Arete and already has made significant contributions to the company. We are confident that his exceptional entrepreneurial leadership will guide the company in the years to come as Arete continues to advance its pipeline of innovative compounds through clinical development," said James Topper, M.D., Ph.D., chairman of the board of Arete Therapeutics Inc. "In addition, on behalf of the board of directors, I would like to thank Dinesh Patel for his dedication and commitment to building a successful biotechnology organization while transitioning Arete from a discovery to a clinical stage company."

Dr. Sabry is chairman of the board of directors and former CEO of Cytokinetics, a company he co-founded in August 1997. Prior to co-founding Cytokinetics, he held faculty positions at the University of California, San Francisco and Harvard Medical School. He serves on the board of directors of HopeLab, a not-for-profit organization developing innovative technologies for the management of cancer, obesity and other diseases, is a member of Dean's Council of the Kennedy School of Government at Harvard University and serves on the advisory boards of numerous organizations including the California Institute of Quantitative Biosciences. Dr. Sabry received an M.D. from Queen's University and a Ph.D. in cell biology from the University of California, San Francisco.

"Arete Therapeutics is uniquely positioned to develop its pipeline of novel soluble epoxide hydrolase inhibitors for multiple disease indications and I look forward to applying my experience to build on the strong foundation and take the company to the next level of strategic and scientific excellence," said Dr. Sabry.

About Arete Therapeutics Inc.

Arete Therapeutics Inc. is a privately-held pharmaceutical company discovering and developing first-in-class small molecule drugs directed at soluble epoxide hydrolase (s-EH), a unique enzyme which plays a key role in the arachidonic acid pathway. Arete has discovered and developed a series of proprietary and chemically diverse molecules with preclinical efficacy in various animal models, and is conducting a phase 1 clinical trial with its first-in-class compound, AR9281. The company has raised a total of $51 million in Series A financing led by Frazier Healthcare Ventures, Alta Partners, Three Arch Partners, Burrill & Company and Altitude Life Science Ventures. For more information on Arete Therapeutics, please visit http://www.aretetherapeutics.com.


'/>"/>
SOURCE Arete Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Santa Clara, CA (PRWEB) , ... February 22, 2017 , ... ... is hosting a free AFM Luncheon for all SPIE attendees ... San Jose, CA, just one block from the San Jose Convention Center. The ...
(Date:2/22/2017)... ... 22, 2017 , ... ProMIS Neurosciences (“ProMIS” or the “Company”), ... today announced it has issued a scientific white paper entitled “Results from recent ... of commentaries from ProMIS’s scientific team offering insight into the Company’s product portfolio ...
(Date:2/22/2017)... Origin (Origin Agritech, LLC, a subsidiary of Origin Agritech Ltd.) (NASDAQ: ... Arcadia (Arcadia Biosciences, Inc., NASDAQ: RKDA), a ... and nutritional products, today announced their collaboration to achieve the first-ever ... China to the United States ... ...
(Date:2/22/2017)... DIEGO , Feb. 22, 2017  Creative ... expansion of its translational research program using its ... of laboratory facilities in San Diego.  The Company ... BioLabs facility, a biotechnology incubator sponsored by the ... In November 2016, the Company obtained an ...
Breaking Biology Technology:
(Date:1/26/2017)... 2017  Acuity Market Intelligence today released the ... Identity".  Acuity characterizes 2017 as a "breakout" year ... reflects a new understanding of the potential benefits ... digital identity are often perceived as threats to ... Principal of Acuity Market intelligence. "However, taken together ...
(Date:1/23/2017)... 23, 2017  The latest mobile market research from ... dropped dramatically. The quarterly average price of a biometric ... in Q4 2016.  There are now 120 sub-$150 models ... up from just 28 a year ago at an ... Maxine Most , Acuity Market Intelligence Principal, "Biometric ...
(Date:1/18/2017)... -- In vitro diagnostic (IVD) companies were very active in ... Kalorama Information expects that trend to continue – though ... uncertainty in reimbursement and healthcare reform in ... acquisitions landscape. Instead of looking to buy technology, the ... of their home country and also to increase their ...
Breaking Biology News(10 mins):